Virpax Pharmaceuticals Ownership 2024 | Who Owns Virpax Pharmaceuticals Now?

Overview ForecastFinancials Chart

Institutional Ownership

0.00%

Insider Ownership

6.26%

Retail Ownership

93.74%

Institutional Holders

1.00

Virpax Pharmaceuticals Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
PARALLEL ADVISORS, LLC	0.00%	-	1	-13	-92.86%	4,000	Mar 31, 2024
JPMORGAN CHASE & CO	-	-	-	-4,358	-100.00%	-	Mar 31, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-67	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-15,221	-100.00%	-	Mar 31, 2024
VANGUARD GROUP INC	-	-	-	-66,294	-100.00%	-	Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-100,875	-100.00%	-	Mar 31, 2024
MORGAN STANLEY	-	-	-	-150	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-30,500	-100.00%	-	Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-50,000	-100.00%	-	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-63,928	-100.00%	-	Mar 31, 2024
BLACKROCK INC.	-	-	-	-464	-100.00%	-	Mar 31, 2024
TWO SIGMA SECURITIES, LLC	-	-	-	-11,695	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,318	-100.00%	-	Mar 31, 2024
UBS GROUP AG	-	-	-	-6,616	-100.00%	-	Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,400	-100.00%	-	Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC	-	-	-	-500	-100.00%	-	Mar 31, 2024

Virpax Pharmaceuticals's largest institutional shareholder is PARALLEL ADVISORS, LLC, holding 0.00% of the company's total share outstanding, currently valued at $4.00K. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
PARALLEL ADVISORS, LLC	0.00%	-	1	-13	-92.86%	4,000	Mar 31, 2024
JPMORGAN CHASE & CO	-	-	-	-4,358	-100.00%	-	Mar 31, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-67	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-15,221	-100.00%	-	Mar 31, 2024
VANGUARD GROUP INC	-	-	-	-66,294	-100.00%	-	Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-100,875	-100.00%	-	Mar 31, 2024
MORGAN STANLEY	-	-	-	-150	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-30,500	-100.00%	-	Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-50,000	-100.00%	-	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-63,928	-100.00%	-	Mar 31, 2024
BLACKROCK INC.	-	-	-	-464	-100.00%	-	Mar 31, 2024
TWO SIGMA SECURITIES, LLC	-	-	-	-11,695	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,318	-100.00%	-	Mar 31, 2024
UBS GROUP AG	-	-	-	-6,616	-100.00%	-	Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,400	-100.00%	-	Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC	-	-	-	-500	-100.00%	-	Mar 31, 2024

The largest Virpax Pharmaceuticals shareholder by % of total assets is PARALLEL ADVISORS, LLC. The company owns 1.00 shares of Virpax Pharmaceuticals (VRPX), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
PARALLEL ADVISORS, LLC	0.00%	-	1	-13	-92.86%	4,000	Mar 31, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-67	-100.00%	-	Mar 31, 2024
MORGAN STANLEY	-	-	-	-150	-100.00%	-	Mar 31, 2024
BLACKROCK INC.	-	-	-	-464	-100.00%	-	Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC	-	-	-	-500	-100.00%	-	Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,400	-100.00%	-	Mar 31, 2024
JPMORGAN CHASE & CO	-	-	-	-4,358	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,318	-100.00%	-	Mar 31, 2024
UBS GROUP AG	-	-	-	-6,616	-100.00%	-	Mar 31, 2024
TWO SIGMA SECURITIES, LLC	-	-	-	-11,695	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-15,221	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-30,500	-100.00%	-	Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-50,000	-100.00%	-	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-63,928	-100.00%	-	Mar 31, 2024
VANGUARD GROUP INC	-	-	-	-66,294	-100.00%	-	Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-100,875	-100.00%	-	Mar 31, 2024

As of Mar 31 2024, Virpax Pharmaceuticals's largest institutional buyer is PARALLEL ADVISORS, LLC. The company purchased -13.00 stocks of VRPX, valued at $4.00K.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-100,875	-100.00%	-	Mar 31, 2024
VANGUARD GROUP INC	-	-	-	-66,294	-100.00%	-	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-63,928	-100.00%	-	Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-50,000	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-30,500	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-15,221	-100.00%	-	Mar 31, 2024
TWO SIGMA SECURITIES, LLC	-	-	-	-11,695	-100.00%	-	Mar 31, 2024
UBS GROUP AG	-	-	-	-6,616	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,318	-100.00%	-	Mar 31, 2024
JPMORGAN CHASE & CO	-	-	-	-4,358	-100.00%	-	Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,400	-100.00%	-	Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC	-	-	-	-500	-100.00%	-	Mar 31, 2024
BLACKROCK INC.	-	-	-	-464	-100.00%	-	Mar 31, 2024
MORGAN STANLEY	-	-	-	-150	-100.00%	-	Mar 31, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-67	-100.00%	-	Mar 31, 2024
PARALLEL ADVISORS, LLC	0.00%	-	1	-13	-92.86%	4,000	Mar 31, 2024

As of Mar 31 2024, Virpax Pharmaceuticals's biggest institutional seller is PNC FINANCIAL SERVICES GROUP, INC.. The company sold -0.10M shares of VRPX, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
PNC FINANCIAL SERVICES GROUP, INC.	-	-	-	-100,875	-100.00%	-	Mar 31, 2024
VANGUARD GROUP INC	-	-	-	-66,294	-100.00%	-	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-63,928	-100.00%	-	Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-50,000	-100.00%	-	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-30,500	-100.00%	-	Mar 31, 2024
NORTHERN TRUST CORP	-	-	-	-15,221	-100.00%	-	Mar 31, 2024
TWO SIGMA SECURITIES, LLC	-	-	-	-11,695	-100.00%	-	Mar 31, 2024
UBS GROUP AG	-	-	-	-6,616	-100.00%	-	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,318	-100.00%	-	Mar 31, 2024
JPMORGAN CHASE & CO	-	-	-	-4,358	-100.00%	-	Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-2,400	-100.00%	-	Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC	-	-	-	-500	-100.00%	-	Mar 31, 2024
BLACKROCK INC.	-	-	-	-464	-100.00%	-	Mar 31, 2024
MORGAN STANLEY	-	-	-	-150	-100.00%	-	Mar 31, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-67	-100.00%	-	Mar 31, 2024

Virpax Pharmaceuticals's largest sold out institutional shareholder by shares sold is PNC FINANCIAL SERVICES GROUP, INC., sold -0.10M shares, valued at -, as of undefined.

Virpax Pharmaceuticals Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
VANGUARD VALLEY FORGE FUNDS	0.01%	6,400	-	-	Dec 31, 2023
FIDELITY CONCORD STREET TRUST	0.00%	60,596	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	132,588	67,443	103.53%	Dec 31, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST	0.00%	556	-	-	Dec 31, 2023

Virpax Pharmaceuticals's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 6.40K shares, compromising 0.01% of its total assets.

Virpax Pharmaceuticals Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 24	1	-93.75%
31 Dec, 23	16	33.33%
30 Sep, 23	12	-7.69%
30 Jun, 23	13	-18.75%
31 Mar, 23	16	-11.11%
31 Dec, 22	18	28.57%
30 Sep, 22	14	7.69%
30 Jun, 22	13	-
31 Mar, 22	13	-18.75%
31 Dec, 21	16	45.45%
30 Sep, 21	11	83.33%
30 Jun, 21	6	50.00%
31 Mar, 21	4	-

As of 31 Mar 24, 1 institutions are holding Virpax Pharmaceuticals's shares, representing a decrease of -93.75% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 24	1	-100.00%
31 Dec, 23	359,400	-41.72%
30 Sep, 23	616,674	-19.42%
30 Jun, 23	765,295	-31.24%
31 Mar, 23	1,113,021	-28.32%
31 Dec, 22	1,552,757	-14.90%
30 Sep, 22	1,824,669	-2.20%
30 Jun, 22	1,865,661	-24.95%
31 Mar, 22	2,485,815	11.20%
31 Dec, 21	2,235,462	-6.24%
30 Sep, 21	2,384,134	870.60%
30 Jun, 21	245,635	-10.67%
31 Mar, 21	274,980	-

Virpax Pharmaceuticals (VRPX) has 1.00 shares outstanding as of 31 Mar 24, down -100.00% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 24	0.00%	-
31 Dec, 23	3.07%	11.07%
30 Sep, 23	5.26%	12.33%
30 Jun, 23	6.53%	7.24%
31 Mar, 23	9.50%	5.41%
31 Dec, 22	13.26%	5.46%
30 Sep, 22	15.58%	6.14%
30 Jun, 22	15.93%	3.53%
31 Mar, 22	21.23%	1.89%
31 Dec, 21	33.48%	2.13%
30 Sep, 21	39.66%	161.64%
30 Jun, 21	4.95%	10.20%
31 Mar, 21	6.97%	-

As of 31 Mar 24, Virpax Pharmaceuticals is held by 0.00% institutional shareholders, representing a 0.00% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 24	-	-100.00%
31 Dec, 23	10	233.33%
30 Sep, 23	3	50.00%
30 Jun, 23	2	-33.33%
31 Mar, 23	3	-62.50%
31 Dec, 22	8	100.00%
30 Sep, 22	4	-50.00%
30 Jun, 22	8	-
31 Mar, 22	8	-38.46%
31 Dec, 21	13	30.00%
30 Sep, 21	10	233.33%
30 Jun, 21	3	-25.00%
31 Mar, 21	4	-

- institutional shareholders have increased their position in VRPX stock as of 31 Mar 24 compared to 10 in the previous quarter (a -100.00% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 24	1	-
31 Dec, 23	1	-66.67%
30 Sep, 23	3	-
30 Jun, 23	3	-40.00%
31 Mar, 23	5	-16.67%
31 Dec, 22	6	50.00%
30 Sep, 22	4	100.00%
30 Jun, 22	2	100.00%
31 Mar, 22	1	-50.00%
31 Dec, 21	2	100.00%
30 Sep, 21	1	-50.00%
30 Jun, 21	2	-
31 Mar, 21	-	-

1 institutional shareholders have reduced their position in VRPX stock as of 31 Mar 24 compared to 1 in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 24	1	-93.75%	1	-100.00%	0.00%	-	-	-100.00%	1	-
31 Dec, 23	16	33.33%	359,400	-41.72%	3.07%	11.07%	10	233.33%	1	-66.67%
30 Sep, 23	12	-7.69%	616,674	-19.42%	5.26%	12.33%	3	50.00%	3	-
30 Jun, 23	13	-18.75%	765,295	-31.24%	6.53%	7.24%	2	-33.33%	3	-40.00%
31 Mar, 23	16	-11.11%	1,113,021	-28.32%	9.50%	5.41%	3	-62.50%	5	-16.67%
31 Dec, 22	18	28.57%	1,552,757	-14.90%	13.26%	5.46%	8	100.00%	6	50.00%
30 Sep, 22	14	7.69%	1,824,669	-2.20%	15.58%	6.14%	4	-50.00%	4	100.00%
30 Jun, 22	13	-	1,865,661	-24.95%	15.93%	3.53%	8	-	2	100.00%
31 Mar, 22	13	-18.75%	2,485,815	11.20%	21.23%	1.89%	8	-38.46%	1	-50.00%
31 Dec, 21	16	45.45%	2,235,462	-6.24%	33.48%	2.13%	13	30.00%	2	100.00%
30 Sep, 21	11	83.33%	2,384,134	870.60%	39.66%	161.64%	10	233.33%	1	-50.00%
30 Jun, 21	6	50.00%	245,635	-10.67%	4.95%	10.20%	3	-25.00%	2	-
31 Mar, 21	4	-	274,980	-	6.97%	-	4	-	-	-

Virpax Pharmaceuticals Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Insider Sells

Date	Name	Relation	Role	Buy/Sell	Shares	Price	Value	Shares Held
Oct 03, 2023	Mathias Sheila	officer	Chief Scientific Officer	Sell	25,000	$4.62	$115.50K	-
Oct 03, 2023	Mathias Sheila	officer	Chief Scientific Officer	Sell	60,676	$2.13	$129.24K	-
Oct 03, 2023	Mathias Sheila	officer	Chief Scientific Officer	Sell	112,000	$0.79	$88.48K	-

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jan 31, 2024	Singh Vanila	director	-	A-Award	Buy	25,000	$0.32	$7.95K	25,000
Jan 31, 2024	Shah Vinay	officer	Chief Financial Officer	A-Award	Buy	112,000	$0.32	$35.59K	112,000
Jan 31, 2024	Jambulingam Thani	director	-	A-Award	Buy	25,000	$0.32	$7.95K	25,000
Jan 31, 2024	Mathias Sheila	officer	Chief Scientific Officer	A-Award	Buy	112,000	$0.32	$35.59K	112,000
Jan 31, 2024	Dubin Michael F	director	-	A-Award	Buy	25,000	$0.32	$7.95K	25,000
Jan 31, 2024	Sendrow Jerrold	director	-	A-Award	Buy	25,000	$0.32	$7.95K	25,000
Jan 31, 2024	Bruce Gerald W	director, officer	Chief Executive Officer	A-Award	Buy	125,000	$0.32	$39.73K	125,000
Jan 31, 2024	Floyd Eric	director	-	A-Award	Buy	45,000	$0.32	$14.30K	45,000
Jan 31, 2024	Ruskin Barbara	director	-	A-Award	Buy	25,000	$0.32	$7.95K	25,000
Oct 03, 2023	Mathias Sheila	officer	Chief Scientific Officer		Sell	25,000	$4.62	$115.50K	-
Oct 03, 2023	Mathias Sheila	officer	Chief Scientific Officer		Sell	60,676	$2.13	$129.24K	-
Oct 03, 2023	Mathias Sheila	officer	Chief Scientific Officer		Sell	112,000	$0.79	$88.48K	-
Aug 16, 2023	Shah Vinay	officer	Chief Financial Officer	A-Award	Buy	100,000	$0.99	$99.00K	100,000
Jun 21, 2023	Shah Vinay	officer	Chief Financial Officer	A-Award	Buy	100,000	$0.99	$99.00K	100,000
Jun 21, 2023	Shah Vinay	officer	-		Buy	-	-	-	-
Apr 26, 2023	Bruce Gerald W	director	-	A-Award	Buy	100,000	$0.73	$73.00K	100,000
Mar 28, 2023	Ruskin Barbara	director	-	A-Award	Buy	25,000	$0.84	$20.91K	25,000
Mar 28, 2023	Ruskin Barbara	director			Buy	-	-	-	-
Feb 07, 2023	Mack Anthony P.	director, 10 percent owner, officer	Chief Executive Officer	A-Award	Buy	125,000	$0.87	$108.38K	125,000
Jan 27, 2023	Gudin Jeffrey	officer	Chief Medical Officer	A-Award	Buy	50,000	-	-	50,000

The last insider sell of Virpax Pharmaceuticals's stock was made by Mathias Sheila on Oct 03 2023, selling 25,000 shares at $4.62 per share (valued at $115.50K).

Virpax Pharmaceuticals Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	9	1	900.00%
Q2 2023	3	-	-
Q1 2023	10	1	1000.00%
Q2 2022	4	1	400.00%
Q1 2022	12	-	-
Q4 2021	2	-	-
Q3 2021	1	1	100.00%
Q2 2021	8	6	133.33%
Q1 2021	2	10	20.00%

9 total buy trades, and 1 total sell trades (buy/sell ratio of 9.00%) were made by Virpax Pharmaceuticals's insiders, as of Q1 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	-	-	-
Q2 2023	-	-	-
Q1 2023	-	-	-
Q2 2022	3	-	-
Q1 2022	-	-	-
Q4 2021	2	-	-
Q3 2021	-	-	-
Q2 2021	-	-	-
Q1 2021	2	-	-

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Virpax Pharmaceuticals's stocks.

Virpax Pharmaceuticals Peer Ownership

Ticker	Company
BDRX	Biodexa Pharmaceuticals Plc
VRAX	Virax Biolabs Group Limited
QNRX	Quoin Pharmaceuticals, Ltd.
NTRB	Nutriband Inc.
PALI	Palisade Bio, Inc.
LGVN	Longeveron Inc.
KPRX	Kiora Pharmaceuticals, Inc.
RNXT	RenovoRx, Inc.
BWV	Onconetix, Inc.
KTTA	Pasithea Therapeutics Corp.
REVB	Revelation Biosciences, Inc.
PRAX	Praxis Precision Medicines, Inc.
HILS	Tharimmune, Inc.
ABIO	ARCA biopharma, Inc.

VRPX Ownership FAQ

Who Owns Virpax Pharmaceuticals?

Virpax Pharmaceuticals is owned by institutional shareholders (0.00%), insiders (6.26%), and public (93.74%). The largest institutional shareholder of Virpax Pharmaceuticals is PARALLEL ADVISORS, LLC (0.00% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.01% of total shares).

Who are the major institutional shareholders of Virpax Pharmaceuticals?

Virpax Pharmaceuticals's major institutional shareholders are PARALLEL ADVISORS, LLC, JPMORGAN CHASE & CO, WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, and VANGUARD GROUP INC. The top five shareholders own together 0.00% of the company's share outstanding.

How many Virpax Pharmaceuticals shareholders are there?

As of Mar 2024, there are 1 institutional shareholders of Virpax Pharmaceuticals.

What percentage of Virpax Pharmaceuticals is owned by PARALLEL ADVISORS, LLC?

PARALLEL ADVISORS, LLC owns 1 shares of Virpax Pharmaceuticals, representing 0.00% of the company's total shares outstanding, valued at $4K (as of Mar 2024).

What percentage of Virpax Pharmaceuticals is owned by JPMORGAN CHASE & CO?

As of Mar 2024, JPMORGAN CHASE & CO holds 0 shares of Virpax Pharmaceuticals (VRPX), compromising 0% of the company, valued at $0.

What percentage of Virpax Pharmaceuticals is owned by WELLS FARGO & COMPANY/MN?

WELLS FARGO & COMPANY/MN is the third largest holder of Virpax Pharmaceuticals. The company owns 0 of the company's shares outstanding (worth $0).